HPC
ADPT icon

HM Payson & Co’s Adaptive Biotechnologies ADPT Stock Holding History

HM Payson & Co’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-489
Closed -$20K – 1085
2021
Q1 		$20K Hold
489
– – ﹤0.01% 753
2020
Q4 		$29K Sell
489
-133
-21% -$6.86K ﹤0.01% 708
2020
Q3 		$30K Buy
+622
New +$26.1K ﹤0.01% 652

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HM Payson & Co's ADPT Position: Q2 2021 in Review

HM Payson & Co sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 489 shares — an estimated $20K sold.

HM Payson & Co first reported a position in ADPT in Q3 2020 and held it in 3 quarters. The position peaked at $30K in Q3 2020. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • HM Payson & Co reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 489 Adaptive Biotechnologies shares in Q2 2021, an estimated $20K.
  • HM Payson & Co first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 3 quarters.
  • HM Payson & Co's Adaptive Biotechnologies position peaked at $30K in Q3 2020.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.